OAI-001 - YOURPGX ONCOLOGY: A NOVEL DIRECT-TO-PATIENT PORTAL FOR DELIVERING PHARMACOGENOMIC (PGX) RESULTS

Y. Cho¹, M. Jack², S. Elahi², R. Knoebel², K. Yeo², D. Meltzer², S. Volchenboum², E. Vokes², R. Szmulewitz², M. Ratain², P. O'Donnell²; ¹UChicago Medicine, Chicago, IL, USA, ²UChicago, Chicago, IL, USA.

Background: Germline PGx is increasingly used to tailor chemotherapy selection/dosing (e.g., DPYD/fluoropyrimidines), but most systems communicate results to providers. We developed an innovative patient-facing portal to deliver PGx results directly to patients with educational content, hypothesizing it would enhance understanding of personalized treatments, engagement in healthcare decisions, and improve perceptions of care.

Methods: YourPGx Oncology was designed to present PGx results for eight key drug-gene pairs using intuitive visuals and lay language, generating 33 unique, patient-focused clinical decision support summaries. The portal was pre-tested among stakeholder groups and refined before formal testing. Patients enrolled in the PhOCus PGx study (NCT04541381) at UChicago were then approached for this prospective sub-study, which offered patients access to YourPGx Oncology during their oncology care. Single-session evaluations were conducted in-person via tablet or via Zoom and observed by a pharmacist member of the research team. Formal pre-and post-surveys assessed educational impact.

Results: Of 188 eligible patients, 49 responded to solicitations via email, phone, and in person, of whom 31 (63.3%) joined the sub-study (19 male, 12 female; 19 White, 8 Black, 4 Other; median age 60, range 32-74). Patients spent a median of 15 minutes (range: 10-20) navigating YourPGx Oncology, with the results section being most viewed. Participants found the portal's information straightforward and appreciated the user-friendly visuals. Survey results showed significant improvements in patient understanding and perceptions of PGx. The belief that providers utilize ‘personalized medicine’ increased from 35.5% to 66.7% (p=0.0311). Patients desiring use of PGx information before oncology prescribing decisions increased (41.9% to 76.7%, p=0.0115). Awareness of potential medication side effects improved, with recall increasing from 54.8% to 90.0% (p=0.0175).

Conclusion: A novel direct-to-patient PGx portal significantly improved patients' understanding and engagement with personal germline PGx information to guide cancer therapy. Future research will explore the impact of direct-to-patient PGx result delivery on treatment outcomes.